NCT07039045

A Study of [14C]-LY4065967 in Healthy Participants

A Phase 1, Open-label, 2-part Study of the Absorption, Metabolism, Excretion, and Bioavailability of [14C]-LY4065967 in Healthy Male Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate the absorption, metabolism, excretion, and bioavailability of LY4065967 in healthy male participants. This is a 2-part study. The study will last about 58 days for participants in Part 1 and about 60 days for participants in Part 2.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY4065967	Oral dose
RADIATION	[14C]-LY4065967 Oral	Oral dose
RADIATION	[14C]-LY4065967 IV	IV dose

Timeline

• Start date: 2025-06-23
• Primary completion: 2025-08-16
• Completion: 2025-08-16
• First posted: 2025-06-26
• Last updated: 2025-09-09

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study